| Patient | Elvis Presley |
|---|---|
| Date of birth | 1935-01-08 |
| Identifiers | MRN HR-ML003-SYN-TD; SSN (made up) 000-03-4417 |
| Document date | 2026-11-01 |
| Author | Coleman Ashby-Nakagawa, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral. Concerns: He is tired all the time, sleepy in the afternoon and cannot keep up the energy his shows need; He has put on weight and feels bloated and constipated, and is self-conscious about it on stage; He wants to stop needing so many pills without going through withdrawal or missing a show. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Hydromorphone 4 mg oral tablet, prescribed elsewhere as one tablet every four to six hours as needed for back and neck pain; taking about five a day (20 mg, 100 MME); continued by this clinic only, at the verified dose and seven days at a time, until the addiction medicine consultation | Up to five tablets a day; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Oxycodone 10 mg and acetaminophen 325 mg oral tablet, prescribed by a second prescriber; taking about three a day (45 MME); continued by this clinic only, seven days at a time, until the consultation | Up to three tablets a day; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Diazepam 10 mg oral tablet, one tablet three times daily, prescribed elsewhere for anxiety; continued by this clinic only, seven days at a time | One tablet three times daily; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Alprazolam 1 mg oral tablet, up to three a day as needed, prescribed by a fourth prescriber while on tour; continued by this clinic only, at the verified dose, seven days at a time | Up to three tablets a day; seven-day supply | Oral route | 1974-07-10 to 1974-07-17 | completed | S |
| Phentermine 37.5 mg oral tablet each morning, prescribed by a weight clinic; stopped today because of high blood pressure and his glaucoma | Stopped | Oral route | 1974-07-10 to 1974-07-10 | completed | S |
| Latanoprost 0.005% eye drops, one drop in each eye at bedtime, prescribed by his ophthalmologist | One drop in each eye at bedtime | Ophthalmic route | 1974-07-10 | active | S |
| Naloxone 4 mg nasal spray, one spray into one nostril for a suspected overdose, repeated in the other nostril after two to three minutes if needed; two-pack, with a second for the tour bag | One spray for a suspected overdose; call 911 | Nasal route | 1974-07-10 | active | S |
| Polyethylene glycol 3350, 17 g powder in a glass of water once daily | 17 g in water once daily | Oral route | 1974-07-10 | active | S |
| Senna 8.6 mg oral tablet, two tablets at bedtime | Two tablets at bedtime | Oral route | 1974-07-10 to 1974-08-07 | completed | S |
| Buprenorphine 8 mg and naloxone 2 mg sublingual film, two films (16 mg) under the tongue once daily, which may be split into one film twice daily; started in the office at the consultation; seven-day supplies at first, from this clinic only | Two films once daily, or one film twice daily | Sublingual route | 1974-07-17 | active | S |
| Diazepam 10 mg oral tablet, one tablet four times daily (40 mg a day), replacing both diazepam 10 mg three times daily and alprazolam; held steady until buprenorphine is stable | One tablet four times daily; seven-day supply | Oral route | 1974-07-17 to 1974-08-07 | completed | S |
| Diazepam 10 mg oral tablet, one tablet three times daily, with diazepam 2 mg tablets for the taper steps; dispensed two weeks at a time | One tablet three times daily with the 2 mg tablets as scheduled | Oral route | 1974-08-07 | active | S |
| Diazepam 2 mg oral tablet on the written taper schedule: three a day (36 mg a day in all) from the three-week visit, one a day (32 mg) from the ten-week visit, stopped at four months (30 mg) | Per the written taper schedule | Oral route | 1974-08-07 to 1974-10-28 | completed | S |
| Amlodipine 5 mg and valsartan 160 mg oral tablet, one tablet daily | One tablet daily | Oral route | 1974-07-17 | active | S |
| Tirzepatide 2.5 mg/0.5 mL auto-injector, 2.5 mg under the skin once weekly | 2.5 mg once weekly | Subcutaneous route | 1974-08-07 to 1974-09-23 | completed | S |
| Tirzepatide 5 mg/0.5 mL auto-injector, 5 mg under the skin once weekly | 5 mg once weekly | Subcutaneous route | 1974-09-23 | active | S |
| Naproxen 500 mg oral tablet, one tablet twice daily with food for five days | One tablet twice daily with food for five days | Oral route | 1974-09-09 to 1974-09-13 | completed | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Twelve-lead electrocardiogram at the evaluation of high blood pressure readings, before any change in his medicines: sinus rhythm at 92, normal axis, no left ventricular hypertrophy, QTc 436 ms | 1974-07-10 to 1974-07-10 | completed | S |
| Attended in-laboratory split-night polysomnography (chosen over home testing because he takes opioids and benzodiazepines): apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80%; CPAP titrated to 11 cm H2O, which controlled events | 1974-07-14 to 1974-07-14 | completed | S |
| Advance care planning conversation, about 20 minutes | 1974-08-14 to 1974-08-14 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 1974-08-14 | Tdap vaccine; last tetanus booster more than ten years ago | completed | S |
| 1974-09-23 | Hepatitis B vaccine (HepB-CpG), first of two doses, after serology showed no immunity | completed | S |
| 1974-10-28 | Hepatitis B vaccine (HepB-CpG), second of two doses | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| 1971 | Glaucoma, with an acute angle-closure episode treated years earlier; under an ophthalmologist's care since | D (CLM-0007) |
| October 15, 1973 | Hospital stay of about two weeks in which, by later testimony, he was withdrawn from narcotic drugs; recorded without detail | D (CLM-0003) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Concern | Status | Evidence |
|---|---|---|
| He is tired all the time, sleepy in the afternoon and cannot keep up the energy his shows need | active | S |
| He has put on weight and feels bloated and constipated, and is self-conscious about it on stage | active | S |
| He wants to stop needing so many pills without going through withdrawal or missing a show | active | S |
Most recent measures: Hemoglobin [Mass/volume] in Blood 15.1 on 1974-07-10; Sodium [Moles/volume] in Serum or Plasma 139 on 1974-07-10; Potassium [Moles/volume] in Serum or Plasma 4.3 on 1974-10-28; Creatinine [Mass/volume] in Serum or Plasma 1.02 on 1974-10-28; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1969)/1.73 sq M 96 on 1974-10-28; Glucose [Mass/volume] in Serum or Plasma 104 on 1974-07-10; Hemoglobin A1c/Hemoglobin.total in Blood 5.5 on 1974-10-28; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 44 on 1974-10-28; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 33 on 1974-10-28; Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma 55 on 1974-10-28; Thyrotropin [Units/volume] in Serum or Plasma 2.1 on 1974-07-10; Albumin/Creatinine [Mass Ratio] in Urine 14 on 1974-07-10; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 4 on 1974-10-28; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 5 on 1974-10-28; Total score [DAST-10] 7 on 1974-07-10; Total score [AUDIT-C] 0 on 1974-07-10; Cholesterol [Mass/volume] in Serum or Plasma 214 on 1974-08-14; Cholesterol in HDL [Mass/volume] in Serum or Plasma 38 on 1974-08-14; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 140 on 1974-08-14; Triglyceride [Mass/volume] in Serum or Plasma 180 on 1974-08-14 [S]
Strengths and supports: engagement in care [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Fatigue, weight gain of about 14 kg in two years, constipation with a bowel movement every five to seven days, loud snoring with daytime sleepiness, and high blood pressure readings, in a man taking two opioids, two benzodiazepines and an appetite suppressant from five prescribers; under evaluation with addiction medicine, a sleep study and home blood pressure readings | resolved | confirmed | R53.83 | S — Synthetic presenting problem anchored to the documented prescribed drugs and weight gain; superseded when the consultation and tests made the diagnoses. |
| Obesity, class 1 (BMI 32.5), with prediabetes (hemoglobin A1c 5.8%); recorded without stigma; weight gain began with long touring schedules, night eating after shows and an appetite suppressant that stopped working | active | confirmed | E66.811 | S — Synthetic modern diagnosis anchored to his documented weight gain. |
| Glaucoma secondary to steroids, both eyes, mild stage, after an acute angle-closure episode treated years ago; intraocular pressure controlled on latanoprost under his ophthalmologist; anticholinergic and sympathomimetic drugs to be avoided | active | confirmed | H40.63X1 | S — Synthetic modern diagnosis anchored to his documented glaucoma and the retrospective interpretation of it as steroid-induced; not a claim about his real eyes. |
| Opioid use disorder, severe, with prescription opioids from more than one prescriber (seven DSM-5-TR criteria, tolerance and withdrawal counted because the opioids were not taken as prescribed); on buprenorphine from the consultation; synthetic modern episode linked to his documented withdrawal from narcotic drugs and prescribed painkillers | active | confirmed | F11.20 | S — Synthetic modern diagnosis made at the addiction medicine consultation; person-first language; not a claim about his real diagnosis. |
| Sedative, hypnotic, or anxiolytic use disorder (benzodiazepines), moderate (five DSM-5-TR criteria), with two benzodiazepines from two prescribers; combined into diazepam and tapering slowly; synthetic modern episode linked to his documented prescribed sedatives | active | confirmed | F13.20 | S — Synthetic modern diagnosis made at the consultation; not a claim about his real diagnosis. |
| Hypertension, stage 2, confirmed by a home average of 146/94 a week after stopping phentermine; ECG and urine albumin normal | active | confirmed | I10 | S — Synthetic modern diagnosis confirmed with home readings, anchored to his documented hypertension. |
| Obstructive sleep apnea, moderate (apnea-hypopnea index 26 an hour, central apnea index 4, oxygen nadir 80% on in-laboratory polysomnography), worsened by opioids and benzodiazepines; on CPAP | active | confirmed | G47.33 | S — Synthetic modern diagnosis from a synthetic sleep study. |
| Opioid-induced constipation (Rome IV), improving after the change to buprenorphine; no alarm features | active | confirmed | K59.03 | S — Synthetic modern diagnosis anchored to his documented blockage of the colon; not a claim about megacolon. |
| Acute low back strain after karate practice, without radicular signs or red flags, in a man on buprenorphine; resolved | resolved | confirmed | S39.012A | S — Synthetic acute injury; not a historical claim. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 1974-07-10 | Hemoglobin [Mass/volume] in Blood | 15.1 | g/dL | 13.2-17.1 g/dL | Normal | S |
| 1974-07-10 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 1974-07-10 | Potassium [Moles/volume] in Serum or Plasma | 4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1974-07-10 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1974-07-10 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1969)/1.73 sq M | 98 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1974-07-10 | Glucose [Mass/volume] in Serum or Plasma | 104 | mg/dL | 70-99 mg/dL | High | S |
| 1974-07-10 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.8 | % | <=5.6% | High | S |
| 1974-07-10 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 72 | U/L | 7-55 U/L | High | S |
| 1974-07-10 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 52 | U/L | 8-48 U/L | High | S |
| 1974-07-10 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 78 | U/L | 8-61 U/L | High | S |
| 1974-07-10 | Thyrotropin [Units/volume] in Serum or Plasma | 2.1 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 1974-07-10 | Albumin/Creatinine [Mass Ratio] in Urine | 14 | mg/g{creat} | <=29 mg/g{creat} | Normal | S |
| 1974-07-10 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 8 | {score} | S | ||
| 1974-07-10 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 9 | {score} | S | ||
| 1974-07-10 | Total score [DAST-10] | 7 | {score} | S | ||
| 1974-07-10 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 1974-08-14 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1974-08-14 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 1974-08-14 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 38 | mg/dL | >=40 mg/dL | Low | S |
| 1974-08-14 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 140 | mg/dL | <=129 mg/dL | High | S |
| 1974-08-14 | Triglyceride [Mass/volume] in Serum or Plasma | 180 | mg/dL | <=149 mg/dL | High | S |
| 1974-08-07 | Potassium [Moles/volume] in Serum or Plasma | 4.4 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1974-08-07 | Creatinine [Mass/volume] in Serum or Plasma | 1.04 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1974-08-07 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1969)/1.73 sq M | 94 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1974-08-07 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 6 | {score} | S | ||
| 1974-08-07 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 8 | {score} | S | ||
| 1974-09-23 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 5 | {score} | S | ||
| 1974-09-23 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 7 | {score} | S | ||
| 1974-10-28 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 1974-10-28 | Creatinine [Mass/volume] in Serum or Plasma | 1.02 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 1974-10-28 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1969)/1.73 sq M | 96 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 1974-10-28 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | <=5.6% | Normal | S |
| 1974-10-28 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 44 | U/L | 7-55 U/L | Normal | S |
| 1974-10-28 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 33 | U/L | 8-48 U/L | Normal | S |
| 1974-10-28 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 55 | U/L | 8-61 U/L | Normal | S |
| 1974-10-28 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 4 | {score} | S | ||
| 1974-10-28 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 5 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 1974-07-10 | Body height | 183 | cm | S |
| 1974-07-10 | Body weight | 109 | kg | S |
| 1974-07-10 | Body mass index (BMI) [Ratio] | 32.5 | kg/m2 | S |
| 1974-07-10 | Systolic blood pressure | 154 | mm[Hg] | S |
| 1974-07-10 | Diastolic blood pressure | 98 | mm[Hg] | S |
| 1974-07-10 | Heart rate | 94 | /min | S |
| 1974-07-10 | Respiratory rate | 16 | /min | S |
| 1974-07-10 | Body temperature | 36.8 | Cel | S |
| 1974-07-10 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1974-07-17 | Body height | 183 | cm | S |
| 1974-07-17 | Body weight | 108.6 | kg | S |
| 1974-07-17 | Body mass index (BMI) [Ratio] | 32.4 | kg/m2 | S |
| 1974-07-17 | Systolic blood pressure | 146 | mm[Hg] | S |
| 1974-07-17 | Diastolic blood pressure | 94 | mm[Hg] | S |
| 1974-07-17 | Heart rate | 102 | /min | S |
| 1974-07-17 | Respiratory rate | 18 | /min | S |
| 1974-07-17 | Body temperature | 37 | Cel | S |
| 1974-07-17 | Oxygen saturation in Arterial blood by Pulse oximetry | 96 | % | S |
| 1974-08-07 | Body height | 183 | cm | S |
| 1974-08-07 | Body weight | 108.2 | kg | S |
| 1974-08-07 | Body mass index (BMI) [Ratio] | 32.3 | kg/m2 | S |
| 1974-08-07 | Systolic blood pressure | 128 | mm[Hg] | S |
| 1974-08-07 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 1974-08-07 | Heart rate | 76 | /min | S |
| 1974-08-07 | Respiratory rate | 14 | /min | S |
| 1974-08-07 | Body temperature | 36.7 | Cel | S |
| 1974-08-07 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1974-09-23 | Body height | 183 | cm | S |
| 1974-09-23 | Body weight | 105.1 | kg | S |
| 1974-09-23 | Body mass index (BMI) [Ratio] | 31.4 | kg/m2 | S |
| 1974-09-23 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1974-09-23 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1974-09-23 | Heart rate | 74 | /min | S |
| 1974-09-23 | Respiratory rate | 14 | /min | S |
| 1974-09-23 | Body temperature | 36.6 | Cel | S |
| 1974-09-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1974-10-28 | Body height | 183 | cm | S |
| 1974-10-28 | Body weight | 102.6 | kg | S |
| 1974-10-28 | Body mass index (BMI) [Ratio] | 30.6 | kg/m2 | S |
| 1974-10-28 | Systolic blood pressure | 122 | mm[Hg] | S |
| 1974-10-28 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 1974-10-28 | Heart rate | 70 | /min | S |
| 1974-10-28 | Respiratory rate | 14 | /min | S |
| 1974-10-28 | Body temperature | 36.6 | Cel | S |
| 1974-10-28 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 1974-08-14 | Body height | 183 | cm | S |
| 1974-08-14 | Body weight | 107.6 | kg | S |
| 1974-08-14 | Body mass index (BMI) [Ratio] | 32.1 | kg/m2 | S |
| 1974-08-14 | Systolic blood pressure | 126 | mm[Hg] | S |
| 1974-08-14 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 1974-08-14 | Heart rate | 74 | /min | S |
| 1974-08-14 | Respiratory rate | 14 | /min | S |
| 1974-08-14 | Body temperature | 36.6 | Cel | S |
| 1974-08-14 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| 1974-09-09 | Body height | 183 | cm | S |
| 1974-09-09 | Body weight | 106 | kg | S |
| 1974-09-09 | Body mass index (BMI) [Ratio] | 31.7 | kg/m2 | S |
| 1974-09-09 | Systolic blood pressure | 134 | mm[Hg] | S |
| 1974-09-09 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 1974-09-09 | Heart rate | 84 | /min | S |
| 1974-09-09 | Respiratory rate | 16 | /min | S |
| 1974-09-09 | Body temperature | 36.7 | Cel | S |
| 1974-09-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 1974-07-10 | Establishing primary care for fatigue, weight gain, constipation, daytime sleepiness and high blood pressure, with many prescribed drugs from several prescribers: a full medication reconciliation and prescription drug monitoring program review, a nonjudgmental substance use assessment, safety, and an addiction medicine referral | finished | S |
| 1974-07-17 | One-week review, seen the same day by addiction medicine: diagnoses, buprenorphine started in the office, the benzodiazepines combined into one, the sleep study and home blood pressure results | finished | S |
| 1974-08-07 | Three-week review on buprenorphine: withdrawal and cravings, the first benzodiazepine taper step, blood pressure treatment, CPAP, constipation and weight, and planning for a Las Vegas engagement | finished | S |
| 1974-09-23 | Ten-week review after the Las Vegas engagement and a back strain: buprenorphine, the taper, weight treatment, sleep apnea and planning for a three-week tour | finished | S |
| 1974-10-28 | Four-month review after the tour: recovery, the taper, blood pressure, weight, liver tests, sleep and the plan ahead | finished | S |
| 1974-08-14 | Periodic adult preventive visit | finished | S |
| 1974-09-09 | Same-day sick visit for low back pain | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Safe prescribing of controlled drugs: a brown-bag reconciliation of every medicine, a prescription drug monitoring program check before every controlled prescription, a written single-prescriber agreement with one pharmacy, urine drug testing explained as part of care, seven-day supplies at first, a locked box, and take-back of unused tablets; no controlled drug stopped abruptly | completed | GL-CDC-OPIOID-2022, GL-CDC-PDMP, GL-BZD-TAPER-2025 | S |
| Addiction medicine consultation to make the substance use diagnoses, start medication for opioid use disorder, and plan the benzodiazepine change and taper | completed | GL-ASAM-OUD-2020, GL-BZD-TAPER-2025 | S |
| Overdose prevention: naloxone nasal spray at home and in the tour bag, two people around him taught to use it, no alcohol or other sedatives, and the danger of opioids with benzodiazepines and with the sleep apnea that is suspected explained | completed | GL-CDC-OPIOID-2022, GL-ASAM-OUD-2020 | S |
| Safety: a structured safety assessment, a written safety plan, firearms locked and unloaded with ammunition separate, the 988 Suicide & Crisis Lifeline, and safety review at every visit; PHQ-9 and GAD-7 at each review | completed | GL-SUICIDE-2024, GL-USPSTF-DEP-2023, GL-CMID-2026 | S |
| Buprenorphine for opioid use disorder: buprenorphine with naloxone started in the office at a COWS score above 8, 16 mg a day, weekly contact for the first month, prescriptions from this clinic only, counseling, and no tapering off while he is doing well; buprenorphine is not withheld because he takes a benzodiazepine | completed | GL-ASAM-OUD-2020, GL-CDC-OPIOID-2022 | S |
| Benzodiazepine change and taper: alprazolam combined into diazepam (40 mg a day), held steady until buprenorphine is stable, then reduced by about 5 to 10% every two to four weeks, paused during engagements, illness or withdrawal symptoms, never stopped abruptly; CBT for anxiety and insomnia alongside; no Z-drug or other sedative in its place | completed | GL-BZD-TAPER-2025 | S |
| Hypertension: home readings confirmed stage 2 hypertension, so two first-line drugs were started in one pill (amlodipine with valsartan), with potassium and creatinine two to four weeks later, a target below 130/80, sodium reduction, activity and weight loss | completed | GL-AHA-HTN-2025, GL-CMID-2026 | S |
| Obstructive sleep apnea: CPAP from the split-night titration, with adherence data reviewed at each visit and a travel machine for tours; no sedative added at night | completed | GL-AASM-PAP-2019, GL-AASM-DX-2017 | S |
| Weight treated without stigma: earlier meals, protein and fiber, more walking and karate between tours, and tirzepatide once weekly, chosen because it also treats obstructive sleep apnea with obesity, raised slowly with a watch on nausea and constipation | completed | GL-AGA-OBESITY-2022, GL-SURMOUNT-OSA-2024 | S |
| Constipation on opioids: polyethylene glycol daily with senna as needed, fluids and fiber; a peripherally acting opioid antagonist only if these fail; an abdominal radiograph only for pain, distension or vomiting | completed | GL-AGA-OIC-2019, GL-AGA-ACG-CIC-2023 | S |
| Glaucoma: latanoprost continued, his ophthalmologist kept informed of every new medicine, no phentermine, decongestant or anticholinergic sleep aid, steroids only when essential and with his ophthalmologist's knowledge, and urgent care for eye pain with halos | completed | GL-AAO-POAG-2020, GL-CMID-2026 | S |
| Performing and touring: no medication change in the week before an engagement, weekly video visits while away, controlled prescriptions sent only to one named pharmacy, a written plan for missed doses, naloxone and any prescribed devices in the tour bag, and a letter he controls for venues | completed | GL-ASAM-OUD-2020, GL-BZD-TAPER-2025 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Stop full-agonist opioids and stabilize on buprenorphine without significant withdrawal | 1974-08-07 | completed | Buprenorphine 16 mg a day since the consultation; no withdrawal after the first day; cravings low | S |
| One prescriber and one pharmacy for all controlled medicines | 1974-09-23 | completed | Monitoring program shows only this clinic's prescriptions since intake | S |
| Lower the diazepam dose slowly, 5 to 10% every two to four weeks, toward stopping | 1974-10-28 | active | 40 mg a day after the alprazolam was combined into it, to 30 mg at four months; no withdrawal symptoms; taper continuing | S |
| Home blood pressure below 130/80 | 1974-08-07 | completed | Home average 146/94 to 126/80 on amlodipine and valsartan | S |
| Lose 5% or more of body weight | 1974-10-28 | completed | 109.0 to 102.6 kg (5.9%) on tirzepatide, with more activity and earlier meals | S |
| CPAP on at least 70% of nights for four hours or more, with less daytime sleepiness | 1974-10-28 | completed | CPAP on 88% of nights; Epworth 14 to 6 | S |
| A bowel movement at least every two days without straining | 1974-08-07 | completed | Every one to two days on buprenorphine and polyethylene glycol | S |
Structured synthetic safety assessment on 1974-07-10: current ideation absent, intent absent, plan absent. Outpatient care with close follow-up. No current or past suicidal ideation. Risk factors reviewed: opioid and sedative use disorders under assessment, taking opioids with benzodiazepines, sleep apnea symptoms, firearms at home, and the stress of touring. Means safety: firearms to be stored locked and unloaded with ammunition separate; all controlled medicines in a locked box, with unused tablets from earlier prescriptions taken back to a pharmacy; seven-day supplies; naloxone at home and in the tour bag, with two people around him taught to use it. A written safety plan was made with him, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in his phone. Safety is reviewed at every visit [S]